There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Unity Biotechnology (UBX – Research Report) and Mineralys Therapeutics, Inc. (MLYS – Research Report) with bullish sentiments.
Unity Biotechnology (UBX)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Unity Biotechnology today and set a price target of $12.00. The company’s shares closed last Monday at $4.65, close to its 52-week low of $2.09.
According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of
Unity Biotechnology has an analyst consensus of Strong Buy, with a price target consensus of $19.00.
See today’s best-performing stocks on TipRanks >>
Mineralys Therapeutics, Inc. (MLYS)
In a report released today, Annabel Samimy from Stifel Nicolaus initiated coverage with a Buy rating on Mineralys Therapeutics, Inc. and a price target of $45.00. The company’s shares closed last Monday at $18.96.
According to TipRanks.com, Samimy is a 4-star analyst with an average return of
Currently, the analyst consensus on Mineralys Therapeutics, Inc. is a Moderate Buy with an average price target of $45.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on UBX:
